Sentinel (cenegermin-bkbj) / Dompe 
Welcome,         Profile    Billing    Logout  

7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sentinel (cenegermin-bkbj) / Dompe
IMAGO, NCT06411145: Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis

Active, not recruiting
4
17
US
OXERVATE® 0.002%, cenegermin-bkbj
Dompé Farmaceutici S.p.A
Neurotrophic Keratitis, Neurotrophic Keratopathy, Corneal Ulcer
06/25
06/25
2021-003749-39: A 4 week, Phase III, multicenter, double-masked, study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A. Studio di 4 settimane, di Fase III, multicentrico, in doppio cieco, per valutare la sicurezza e l'efficacia della soluzione oftalmica di Oxervate® (cenegermin) 20 mcg/mL in pazienti affetti da sindrome dell'occhio secco di Sjögren grave in trattamento con Ciclosporina A

Not yet recruiting
3
48
Europe
OXERVATE, [Recombinant Human Nerve Growth Factor (rhNGF)], Eye drops, Oxervate
DOMPé FARMACEUTICI S.P.A., Dompé farmaceutici S.p.A.
Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Diseases [C] - Eye Diseases [C11]
 
 
2021-003346-21: A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren’s dry eye disease. Studio di fase III, multicentrico, di 4 settimane, a doppio mascheramento, controllato con veicolo, volto a valutare la sicurezza e l'efficacia di Oxervate® (cenegermin) 20 mcg/ml soluzione oftalmica rispetto al veicolo, in pazienti affetti da sindrome dell'occhio secco di Sjögren grave.

Not yet recruiting
3
100
Europe
OXERVATE, [Recombinant Human Nerve Growth Factor (rhNGF)], Eye drops, Oxervate
DOMPé FARMACEUTICI S.P.A., Dompé farmaceutici S.p.A.
Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Severe Sjogren’s dry eye disease Sindrome dell'occhio secco di Sjögren grave, Diseases [C] - Eye Diseases [C11]
 
 
NGF0121, NCT05133180: Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)

Completed
3
104
Europe, US
Oxervate, Cenegermin, Vehicle, Reference product
Dompé Farmaceutici S.p.A
Dry Eye
09/22
12/22
NGF0221 - PROTEGO-2, NCT05136170: Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

Completed
3
85
Europe, US
Oxervate, Cenegermin, Vehicle, Placebo
Dompé Farmaceutici S.p.A
Dry Eye Syndrome
03/23
05/23
REDUCO, NCT06244316: A Study to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution in Patients With Dry Eye Disease

Recruiting
2
291
Europe, US
rhNGF concentration 1, rhNGF concentration 2, Vehicle (Placebo solution)
Dompé Farmaceutici S.p.A
Dry Eye Disease
09/24
09/24
DEFENDO, NCT05552261: Long Term Follow-up Study in Stage 1 NK Patients

Recruiting
N/A
37
US
Cenegemin in the DEFENDO Study, OXERVATE™
Dompé Farmaceutici S.p.A
Neurotrophic Keratitis
09/24
09/24

Download Options